长春高新：9月17日召开董事会会议

Group 1 - The core point of the article is that Changchun High-tech (SZ 000661) announced a collaboration with Danish company ALK-Abelló A/S for allergen-specific immunotherapy (AIT) products during its board meeting on September 17, 2025 [1] - For the first half of 2025, the revenue composition of Changchun High-tech was as follows: 92.83% from the pharmaceutical industry, 6.81% from real estate, and 0.36% from services [1] - As of the report date, the market capitalization of Changchun High-tech was 50.5 billion yuan [1]